Nivalis registers $60 million of stock for its initial public offering

Financing to be conducted by Cowen, Stifel, Baird and H.C. Wainwright

By Devika Patel

Knoxville, Tenn., May 13 – Nivalis Therapeutics, Inc. will price its initial public sale of common stock with a 30-day greenshoe, according to a Form S-1 filed Wednesday with the Securities and Exchange Commission. The company has registered up to $60 million of stock for the deal.

Cowen and Co. and Stifel are the bookrunners, and Baird and H.C. Wainwright & Co. are the co-managers.

Proceeds will be used for clinical programs, and development activities and for working capital and other general corporate purposes, including operations.

The clinical stage pharmaceutical company is based in Boulder, Colo. The company intends to list its common stock on the Nasdaq under the symbol “NVLS.”

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.